Citius Oncology Statistics
Total Valuation
Citius Oncology has a market cap or net worth of $100.87 million. The enterprise value is $94.52 million.
| Market Cap | 100.87M |
| Enterprise Value | 94.52M |
Important Dates
The last earnings date was Friday, August 14, 2026, after market close.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Citius Oncology has 105.76 million shares outstanding. The number of shares has increased by 31.40% in one year.
| Current Share Class | 105.76M |
| Shares Outstanding | 105.76M |
| Shares Change (YoY) | +31.40% |
| Shares Change (QoQ) | +7.86% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 5.20% |
| Float | 30.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 14.44 |
| Forward PS | 1.48 |
| PB Ratio | 2.54 |
| P/TBV Ratio | 2.54 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 13.54 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.73, with a Debt / Equity ratio of 0.25.
| Current Ratio | 0.73 |
| Quick Ratio | 0.29 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -129.05 |
Financial Efficiency
Return on equity (ROE) is -126.58% and return on invested capital (ROIC) is -68.37%.
| Return on Equity (ROE) | -126.58% |
| Return on Assets (ROA) | -29.12% |
| Return on Invested Capital (ROIC) | -68.37% |
| Return on Capital Employed (ROCE) | -89.06% |
| Weighted Average Cost of Capital (WACC) | 21.79% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.07 |
| Inventory Turnover | 0.09 |
Taxes
In the past 12 months, Citius Oncology has paid $189,923 in taxes.
| Income Tax | 189,923 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -48.16% in the last 52 weeks. The beta is 3.53, so Citius Oncology's price volatility has been higher than the market average.
| Beta (5Y) | 3.53 |
| 52-Week Price Change | -48.16% |
| 50-Day Moving Average | 0.74 |
| 200-Day Moving Average | 0.89 |
| Relative Strength Index (RSI) | 63.16 |
| Average Volume (20 Days) | 64,744 |
Short Selling Information
The latest short interest is 468,965, so 0.44% of the outstanding shares have been sold short.
| Short Interest | 468,965 |
| Short Previous Month | 452,413 |
| Short % of Shares Out | 0.44% |
| Short % of Float | 1.51% |
| Short Ratio (days to cover) | 3.78 |
Income Statement
In the last 12 months, Citius Oncology had revenue of $7.11 million and -$46.06 million in losses. Loss per share was -$0.49.
| Revenue | 7.11M |
| Gross Profit | 5.32M |
| Operating Income | -47.47M |
| Pretax Income | -45.87M |
| Net Income | -46.06M |
| EBITDA | n/a |
| EBIT | -47.47M |
| Loss Per Share | -$0.49 |
Balance Sheet
The company has $16.56 million in cash and $10.21 million in debt, with a net cash position of $6.35 million or $0.06 per share.
| Cash & Cash Equivalents | 16.56M |
| Total Debt | 10.21M |
| Net Cash | 6.35M |
| Net Cash Per Share | $0.06 |
| Equity (Book Value) | 40.38M |
| Book Value Per Share | 0.38 |
| Working Capital | -16.08M |
Cash Flow
| Operating Cash Flow | -19.39M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | 9.64M |
| Free Cash Flow | -5.49M |
| FCF Per Share | -$0.05 |
Margins
| Gross Margin | 74.82% |
| Operating Margin | -668.15% |
| Pretax Margin | -645.64% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Citius Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -31.40% |
| Shareholder Yield | -31.40% |
| Earnings Yield | -44.90% |
| FCF Yield | -5.35% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Citius Oncology has an Altman Z-Score of -1.88 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.88 |
| Piotroski F-Score | 2 |